Santhera Pharmaceuticals Holding AG (SANN) - Net Assets

Latest as of December 2025: CHF-11.82 Million CHF ≈ $-14.94 Million USD

Based on the latest financial reports, Santhera Pharmaceuticals Holding AG (SANN) has net assets worth CHF-11.82 Million CHF (≈ $-14.94 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF148.09 Million ≈ $187.22 Million USD) and total liabilities (CHF159.90 Million ≈ $202.16 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Santhera Pharmaceuticals Holding AG tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CHF-11.82 Million
% of Total Assets	-7.98%
Annual Growth Rate	N/A
5-Year Change	-989.76%
10-Year Change	-115.89%
Growth Volatility	809.87

Santhera Pharmaceuticals Holding AG - Net Assets Trend (2006–2025)

This chart illustrates how Santhera Pharmaceuticals Holding AG's net assets have evolved over time, based on quarterly financial data. See how many days can Santhera Pharmaceuticals Holding AG fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Santhera Pharmaceuticals Holding AG (2006–2025)

The table below shows the annual net assets of Santhera Pharmaceuticals Holding AG from 2006 to 2025. For live valuation and market cap data, see market value of Santhera Pharmaceuticals Holding AG.

Year	Net Assets	Change
2025-12-31	CHF-11.82 Million ≈ $-14.94 Million	-142.66%
2024-12-31	CHF27.70 Million ≈ $35.02 Million	-53.79%
2023-12-31	CHF59.94 Million ≈ $75.78 Million	+237.21%
2022-12-31	CHF-43.69 Million ≈ $-55.23 Million	-3389.61%
2021-12-31	CHF1.33 Million ≈ $1.68 Million	+120.90%
2020-12-31	CHF-6.35 Million ≈ $-8.03 Million	-129.91%
2019-12-31	CHF21.25 Million ≈ $26.86 Million	-23.65%
2018-12-31	CHF27.83 Million ≈ $35.18 Million	-13.72%
2017-12-31	CHF32.26 Million ≈ $40.78 Million	-56.62%
2016-12-31	CHF74.35 Million ≈ $94.00 Million	-30.02%
2015-12-31	CHF106.25 Million ≈ $134.32 Million	+516.35%
2014-12-31	CHF17.24 Million ≈ $21.79 Million	+142.58%
2013-12-31	CHF7.11 Million ≈ $8.98 Million	-39.42%
2012-12-31	CHF11.73 Million ≈ $14.83 Million	-72.71%
2011-12-31	CHF42.98 Million ≈ $54.34 Million	-38.27%
2010-12-31	CHF69.63 Million ≈ $88.03 Million	-16.63%
2009-12-31	CHF83.51 Million ≈ $105.58 Million	-20.06%
2008-12-31	CHF104.47 Million ≈ $132.08 Million	-22.91%
2007-12-31	CHF135.51 Million ≈ $171.33 Million	-10.87%
2006-12-31	CHF152.05 Million ≈ $192.23 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Santhera Pharmaceuticals Holding AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 57336800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	CHF1.40 Million	%
Other Comprehensive Income	CHF-1.19 Million	%
Other Components	CHF651.90 Million	%
Total Equity	CHF-11.82 Million	100.00%

Santhera Pharmaceuticals Holding AG Competitors by Market Cap

The table below lists competitors of Santhera Pharmaceuticals Holding AG ranked by their market capitalization.

Company	Market Cap
Caisse régionale de Crédit Agricole Mutuel Atlantique Vendée PA:CRAV	$243.55 Million
Dimand S.A. AT:DIMAND	$243.68 Million
Monogram Orthopaedics Inc. Common Stock NASDAQ:MGRM	$243.79 Million
Okins Electronics Co. Ltd KQ:080580	$243.89 Million
Dong-A St KO:170900	$243.45 Million
Bangkok Land Public Company Limited BK:BLAND	$243.39 Million
BROOGE ENERGY DL-0001 F:3SF	$243.29 Million
Aviat Networks Inc NASDAQ:AVNW	$243.13 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Santhera Pharmaceuticals Holding AG's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 27,698,000 to -11,816,000, a change of -39,514,000 (-142.7%).
Net loss of 49,236,000 reduced equity.
New share issuances of 660,000 increased equity.
Other comprehensive income increased equity by 2,107,000.
Other factors increased equity by 6,955,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CHF-49.24 Million	-416.69%
Share Issuances	CHF660.00K	+5.59%
Other Comprehensive Income	CHF2.11 Million	+17.83%
Other Changes	CHF6.96 Million	+58.86%
Total Change	CHF-	-142.66%

Book Value vs Market Value Analysis

This analysis compares Santhera Pharmaceuticals Holding AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	CHF777.00	CHF15.32	x
2007-12-31	CHF437.06	CHF15.32	x
2008-12-31	CHF330.11	CHF15.32	x
2009-12-31	CHF235.61	CHF15.32	x
2010-12-31	CHF190.27	CHF15.32	x
2011-12-31	CHF117.28	CHF15.32	x
2012-12-31	CHF31.90	CHF15.32	x
2013-12-31	CHF19.16	CHF15.32	x
2014-12-31	CHF36.65	CHF15.32	x
2015-12-31	CHF193.76	CHF15.32	x
2016-12-31	CHF118.52	CHF15.32	x
2017-12-31	CHF51.45	CHF15.32	x
2018-12-31	CHF40.38	CHF15.32	x
2019-12-31	CHF19.33	CHF15.32	x
2020-12-31	CHF-4.77	CHF15.32	x
2021-12-31	CHF0.39	CHF15.32	x
2022-12-31	CHF-7.17	CHF15.32	x
2023-12-31	CHF5.49	CHF15.32	x
2024-12-31	CHF2.43	CHF15.32	x
2025-12-31	CHF-0.91	CHF15.32	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Santhera Pharmaceuticals Holding AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -63.79%
• Asset Turnover: 0.52x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-262.59%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	-18.58%	-3618.18%	0.00x	1.07x	CHF-43.46 Million
2007	-20.57%	-302.09%	0.06x	1.06x	CHF-41.42 Million
2008	-42.74%	-93033.33%	0.00x	1.08x	CHF-55.10 Million
2009	31.04%	1577.78%	0.02x	1.13x	CHF17.57 Million
2010	-16.17%	-54.62%	0.26x	1.13x	CHF-18.22 Million
2011	-64.76%	-852.62%	0.06x	1.21x	CHF-32.14 Million
2012	-268.10%	-888.86%	0.19x	1.56x	CHF-32.62 Million
2013	-80.99%	-436.32%	0.14x	1.37x	CHF-6.47 Million
2014	-43.71%	-290.78%	0.11x	1.33x	CHF-9.26 Million
2015	5.60%	137.68%	0.04x	1.10x	CHF-4.68 Million
2016	-47.63%	-186.07%	0.21x	1.22x	CHF-42.85 Million
2017	-159.76%	-224.61%	0.21x	3.40x	CHF-54.76 Million
2018	-194.71%	-171.17%	0.29x	3.96x	CHF-56.97 Million
2019	-89.30%	-25.17%	0.66x	5.41x	CHF-21.10 Million
2020	0.00%	-450.82%	0.17x	0.00x	CHF-67.02 Million
2021	-4181.17%	0.00%	-0.02x	68.61x	CHF-55.66 Million
2022	0.00%	-951.10%	0.12x	0.00x	CHF-66.71 Million
2023	91.39%	52.97%	0.94x	1.83x	CHF48.79 Million
2024	-151.54%	-107.30%	0.26x	5.51x	CHF-44.74 Million
2025	0.00%	-63.79%	0.52x	0.00x	CHF-48.05 Million

Industry Comparison

This section compares Santhera Pharmaceuticals Holding AG's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $368,422,079
Average return on equity (ROE) among peers: -64.38%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Santhera Pharmaceuticals Holding AG (SANN)	CHF-11.82 Million	-18.58%	N/A	$243.45 Million
Addex Therapeutics Ltd (ADXN)	$16.93 Million	-91.05%	0.33x	$6.98 Million
Bachem Holding AG (BANB)	$365.36 Million	11.28%	0.36x	$5.20 Billion
BB Biotech AG (BION)	$3.00 Billion	-26.71%	0.07x	$2.48 Billion
Bioversys AG (BIOV)	$10.68 Million	-175.24%	2.27x	$161.41 Million
Basilea Pharmaceutica AG (BSLN)	$-92.96 Million	0.00%	0.00x	$686.09 Million
Idorsia Ltd (IDIA)	$164.35 Million	-300.98%	5.11x	$1.03 Billion
MINDMAZE THERAPEUTICS HOLDING SA (MMTX)	$38.34 Million	-25.84%	0.34x	$47.52 Million
Molecular Partners AG (MOLN)	$135.79 Million	-13.71%	0.36x	$145.86 Million
Newron Pharmaceuticals SpA (NWRN)	$-14.03 Million	0.00%	0.00x	$297.11 Million
Relief Therapeutics Holding AG (RLF)	$56.73 Million	-21.53%	0.15x	$36.33 Million

About Santhera Pharmaceuticals Holding AG

SW:SANN Switzerland Biotechnology

Market Cap

$275.43 Million

CHF217.85 Million CHF

Market Cap Rank

#15862 Global

#169 in Switzerland

Share Price

CHF15.32

Change (1 day)

+2.00%

52-Week Range

CHF9.58 - CHF18.54

All Time High

CHF1070.00